Kate is currently SVP of the Strategy, Portfolio and Operations organization at GlaxoSmithKline as part of the R&D Executive Team, and is accountable for R&D strategy and performance, pipeline growth and renewal, transformational change delivery and innovation.
Kate joined GSK in 2001 having worked previously at Eli Lilly, AstraZeneca and the BBC, and has previously held a number of leadership positions in areas such as HIV, Respiratory, Diabetes, Oncology and Neuroscience, working across early commercialization to late-lifecycle management phase on a number of the industry’s best-known medicines. Kate was part of the team that created the GSK/Pfizer ViiV joint venture and has led a number of other strategic partnerships and external collaborations across pharma.
Previously Kate also ran GSK’s Global Future Strategy Group for next-generation leaders, focusing on areas such as the sustainability of pharmaceutical reimbursement and access, the role of disruptive innovation in transforming the pharma model and on how to generate organisational agility and a culture of continuous transformation and reinvention.
Kate has received a number of awards during her career including the 2017 Healthcare Businesswomens Association Luminary Award, an accolade recognizing individuals who are role models and have made a significant contribution to the overall success of our industry and those within it. The award focuses on individual impact, leadership and developing others, and Kate was particularly called out for her ability to inspire, mentor and advocate during a 20 year career across the industry in Commercial, Corporate and R&D leadership roles.